adivo Exit

adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.

Press releases

Press

15. September 2023

Successful exit for HTGF: adivo joins Zoetis to bring the benefits of species-specific antibody therapies to pet owners worldwide

adivo’s team and platform will strengthen Zoetis’ capabilities in therapeutic antibody drug discovery for companion animals. High-Tech Gründerfonds (HTGF) was among the first investors in a seed round in 2018 together with OCCIDENT and MorphoSys AG and closely supported the successful development of adivo. Dr. Kathrin Ladetzki-Baehs, Founder and CEO of adivo: “I look forward to seeing what our team can achieve as part of a leading organization with global reach while continuing

Press

20. August 2018

Pet therapeutic antibody firm adivo announces closure of seed-financing round

German biotech company adivo specializing in generating species-specific therapeutic antibodies for companion animals announces that it received a seed financing from three investors. The adivo team aims to address high medical needs in dogs including cancer and chronic inflammation, with the potential of expanding activities into the development of therapeutics for other species in the future. “Now, we are very pleased to have gained three strong and reliable partners that share our vision